论文部分内容阅读
近年来,随着对乳腺癌的认识进入分子水平,医生们己经知道决定乳腺癌命运的不是肿瘤是否进入晚期(指临床分型第Ⅳ期),而是肿瘤的生物行为,如激素(雌、孕激素)受体水平、特殊基因(如HER-2)表达情况等。对于传统的肿瘤治疗方法,雌、孕激素受体阳性的乳腺癌患者效果会好些,HER-2高表达者就危险些,而所谓“三阴型”则更难治。这后两类乳腺癌需要采用
In recent years, with the recognition of breast cancer into the molecular level, doctors have known that the fate of breast cancer is not the tumor into advanced stage (referring to the clinical stage Ⅳ), but the biological behavior of the tumor, such as hormones , Progesterone) receptor level, the expression of special genes (such as HER-2) and so on. For traditional cancer treatment, estrogen and progesterone receptor-positive breast cancer patients will be more effective, HER-2 overexpression were more dangerous, while the so-called “triple negative ” is more difficult to rule. The latter two types of breast cancer need to be used